Join the #FierceMadness!
Pick your favorite drug names in this year's tournament challenge. Read more and vote here!
BN's cancer vaccine CV301 is already under evaluation with Keytruda in NSCLC and with Tecentriq in bladder cancer.
AstraZeneca's FluMist is one step closer to making its return next flu season.
Here is some other vaccine news of note for the week.
After two refusals from Sanofi to provide a refund for the Dengvaxia program, officials in the Philippines say they are getting ready to sue.
Flu vaccine specialist Seqirus grew sales 26% in the six months leading up to Dec. 31, driven by a portfolio shift.
The loan and the $192 million cash left at the end of 2017 will support a Heplisav-B sales team and the clinical trials of SD-101.
Vaccine protection against H3N2 viruses—the predominant strain that tends to cause more severe illness—was only 25% this year.
While only in the very early stages of its important Shingrix launch, GlaxoSmithKline turned in enough vaccine sales to lead the industry in 2017.
The two new grants will support development of universal flu and malaria vaccines leveraging CureVac’s RNActive mRNA-based platform.